Patients with late-stage lung and skin cancer may have just won an unlikely ally: the COVID-19 mRNA vaccine. Researchers at ...

Fintel reports that on October 20, 2025, Needham reiterated coverage of Moderna (NasdaqGS:MRNA) with a Hold recommendation.

An analysis of patient records suggests that mRNA covid-19 vaccines boost the immune response to cancerous tumours when given ...

Over the last year, Noubar Afeyan has watched Cambridge-based Moderna go from perhaps the world’s most celebrated company ...

Multilateral initiatives are needed to signal confidence and fill funding gaps in mRNA research, writes Jennifer B Nuzzo ...

Researchers found that among cancer patients getting immunotherapy, those who got an mRNA Covid vaccine within 100 days ...

An international team led by Monash University researchers has uncovered the genetic code governing the way genetic mutations ...

RNA vaccines are quick and easy to make, while virus-like nanoparticles produce a stronger immune response. Now, the two ...

Patients with cancer who received mRNA-based COVID vaccines within 100 days of starting immune checkpoint therapy were twice ...

Patients with advanced lung or skin cancer who received a COVID-19 mRNA vaccine within 100 days of starting immunotherapy ...

In the current study, the association between mRNA COVID vaccination and survival was strongest among patients whose tumors ...